Pamidronic acid
As of the edition of 20 October 2026, Pamidronic acid is a small molecule: marketed, first approved in 1991 (US); acts on FDPS; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Aredia
- First approved
- 31 October 1991 (US)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Pfizer; 3 holders in all
- Registered trials
- 26, 4 stopped early
- Disease areas
- Bones, joints and muscles; Cancer; Blood and lymph; Heart and blood vessels; Immune system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Pamidronic acid.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | P14324 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 1 | 2 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 10 | 7 | 0 | 2 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 5 | 5 | 0 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator and Lead sponsor of trials | 1991 to now |
| Pfizer | Applicant | 2001 to now |
| Hikma Pharmaceuticals | Acquired holder | 2021 to now |